Shionogi Signs ¥20 Billion License With Oncotherapy Science And Enters Cancer Vaccine Business
This article was originally published in PharmAsia News
Executive Summary
Osaka-based Shionogi signed a licensing agreement with Kawasaki-based biotech venture company Oncotherapy Science and obtained exclusive worldwide rights to develop and market the company's cancer vaccines. Billed as the biggest deal between a Japanese drug maker and a domestic drug discovery venture company, the deal includes a one-time payment, milestone fees and royalties estimated at roughly ¥20 billion. Listed in Tokyo Stock Exchange's Mothers market, Oncotherapy Science specializes in developing cancer vaccines. Shionogi will obtain pre-clinical trial vaccine candidates whose efficacy and develop them in house. (Click here for more - Japanese language
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.